Patel, md, discusses the fda approval of cemiplimab in cutaneous squamous cell carcinoma This new approval is intended for patients who have. Regeneron pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (cscc) who are at a high risk of recurrence following surgery and radiation.
1 libtayo was reviewed by fda under priority review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of. This approval brings hope to adults with cscc who are at high risk of the cancer coming back, offering another way to lower the chances of recurrence Cemiplimab is the first immunotherapy approved for adjuvant treatment in cscc, offering a new option for patients at high risk of recurrence.
